Previous Statements by MYL
» Mylan's CEO Discusses Q1 2012 Results - Earnings Call Transcript
» Mylan, Inc. - Analyst/Investor Day
» Mylan's CEO Discusses Q3 2011 Results - Earnings Call Transcript
The drug maker's shares have fallen 6.2% since Wednesday's market open.
An appeals court in Indiana upheld Eli Lilly's patent regarding Alimta, a major cancer drug for Lilly, keeping Teva and other generic drug specialists at bay.